TargetMol

[D-Ala2]-GIP (human)

Product Code:
 
TAR-TP2019
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP2019-5mg5mg£401.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Highly potent GIP receptor agonist (EC50 = 630 ? 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insulin release and cognitive function in various animal models of obesity and diabetes. Displays neuroprotective effects in an MPTP model of PD.
CAS:
444073-04-5
Formula:
C226H338N60O66S
Molecular Weight:
4983.58
Purity:
0.98
SMILES:
0

References

Porter et al (2011) Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur.J.Pharmacol. 650 688 PMID: Verma et al (2017) Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice. Eur.J.Pharmacol. 804 38 PMID: Hinke et al (2002) Dipeptidyl peptidase IV-resistant [D-Ala2]glucose-dependent Insotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 51 652 PMID: